Skip to content

Study · Observational study · n = 2,247 · 2025

5 results

Association of tirzepatide with glycaemic control and weight loss in a real world cohort of patients with type 2 diabetes from the United States.

Mody R, Desai K, Teng CC, Reznor G, Stockbower G, Grabner M, Benneyworth BD

Diabetes, obesity & metabolism4 Apr 2025Cited by 6 (Europe PMC)

PMID40181696 (opens in a new tab)DOI10.1111/dom.16372 (opens in a new tab)PepBankPUB-40181696
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes who started tirzepatide, 69% had an HbA1c below 7% at 6-month follow-up.

    In plain wordsIn US adults with type 2 diabetes starting tirzepatide, 69% had HbA1c below 7% after 6 months. No comparison group.

    Peptide
    Tirzepatide
    Outcome
    Not applicableProportion with HbA1c below 7% at 6 months
    Study

    n = 2,247

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Proportion with HbA1c <7%
    69%
    overall cohort

    Source sentences

    Summary
    At 6-month follow-up, a majority of the cohort (69%) had an HbA1c <7%, which was higher (77%) in the GLP-1 RA naïve subgroup.
    1 context sentence
    Summary · context
    Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6-month follow-up period were identified.
  2. 02HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes who started tirzepatide, mean weight change at 6 months was -6.3 kg in the overall cohort.

    In plain wordsIn US adults with type 2 diabetes who started tirzepatide, average weight fell by 6.3 kg over 6 months. There was no comparison group.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight change at 6 months
    Study

    n = 2,247

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean weight change
    −6.3 kg
    overall cohort

    Source sentences

    Summary
    Mean change in weight was: -6.3 kg for the overall cohort; -7.1 kg in patients with baseline HbA1c <7%; and -8.1 kg in the GLP-1 RA naïve subgroup.
    1 context sentence
    Summary · context
    Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6-month follow-up period were identified.
  3. 03HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes who started tirzepatide and were GLP-1 receptor agonist naive, 77% had an HbA1c below 7% at 6-month follow-up.

    In plain wordsIn US adults with type 2 diabetes who had not used GLP-1 drugs before, about 77% had HbA1c below 7% after 6 months on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableProportion with HbA1c below 7% at 6 months in GLP-1 RA naive patients
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Proportion with HbA1c <7%
    77%
    GLP-1 RA naive subgroup

    Source sentences

    Summary
    At 6-month follow-up, a majority of the cohort (69%) had an HbA1c <7%, which was higher (77%) in the GLP-1 RA naïve subgroup.
    1 context sentence
    Summary · context
    Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6-month follow-up period were identified.
  4. 04HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes and baseline HbA1c below 7% who started tirzepatide, mean weight change at 6 months was -7.1 kg.

    In plain wordsIn US adults with type 2 diabetes and lower starting HbA1c, average weight fell by 7.1 kg over 6 months on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight change at 6 months in patients with baseline HbA1c below 7%
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean weight change
    −7.1 kg
    baseline HbA1c <7%

    Source sentences

    Summary
    Mean change in weight was: -6.3 kg for the overall cohort; -7.1 kg in patients with baseline HbA1c <7%; and -8.1 kg in the GLP-1 RA naïve subgroup.
    1 context sentence
    Summary · context
    Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6-month follow-up period were identified.
  5. 05HumanObservational studyEfficacy outcome

    In US adults with type 2 diabetes who were GLP-1 receptor agonist naive and started tirzepatide, mean weight change at 6 months was -8.1 kg.

    In plain wordsIn US adults with type 2 diabetes who had not used GLP-1 drugs before, average weight fell by 8.1 kg over 6 months on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight change at 6 months in GLP-1 RA naive patients
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean weight change
    −8.1 kg
    GLP-1 RA naive subgroup

    Source sentences

    Summary
    Mean change in weight was: -6.3 kg for the overall cohort; -7.1 kg in patients with baseline HbA1c <7%; and -8.1 kg in the GLP-1 RA naïve subgroup.
    1 context sentence
    Summary · context
    Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6-month follow-up period were identified.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.